Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FPPRGD2 PET/CT and PET/MRI in Vascular Inflammation
NCT02995642Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-FPPRGD2 in abdominal aortic aneurysm (AAA) and carotid atheroma (CAS), sponsored by Stanford University. Primary endpoints: Maximum Standardized Uptake Value and Percent agreement of 18F-FPPRGD2 PET with pathology. Planned start Oct 2019; status: withdrawn.
02
Drugs
18F-FPPRGD2
03
Conditions
abdominal aortic aneurysm (AAA)carotid atheroma (CAS)
Beyond the preview
Go deeper on NCT02995642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995642.